Dr. Charles DeCarli's Alzheimer's study, a critical six-year effort aimed at understanding dementia risk factors among diverse populations, was unexpectedly terminated by the NIH. The funding discontinuation reflects a broader trend under the current administration, which has reduced support for scientific research, provoking concerns about a potential brain drain of talent from U.S. institutions. With millions affected by Alzheimer'sâa condition projected to double in prevalence among the aging populationâcritics question the rationale behind sidelining research that could yield important insights into this serious public health issue, especially work connected with diversity and equity.
Dr. Charles DeCarli's six-year Alzheimer's study was terminated by the NIH for not meeting agency priorities, despite its importance in understanding dementia risk factors.
The termination highlights the broader issue of diminishing federal support for scientific research under the current administration, raising concerns about a potential brain drain.
DeCarli believes his study was targeted due to its focus on diversity and equity in Alzheimerâs research, which remains critical given the demographic changes.
With Alzheimer's expected to rise significantly in coming decades, cutting vital research funding contradicts the urgent need for better understanding of this devastating disease.
Collection
[
|
...
]